Lacutamab Emerging Drug Insight

“Lacutamab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Lacutamab for Cutaneous T-cell lymphoma (CTCL) in the seven major markets. A detailed picture of the Lacutamab for Cutaneous T-cell lymphoma  in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the Lacutamab for Cutaneous T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Lacutamab market forecast, analysis for Cutaneous T-cell lymphoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cutaneous T-cell lymphoma.

Drug Summary

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody being developed for the treatment of CTCL. KIR3DL2 is an inhibitory receptor of the KIR family. It has a restricted expression on normal tissues. The drug is currently in Phase II of a clinical study for sezary syndrome and mycosis fungoides.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation, and the US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies. Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

In December 2022, the company presented data from a preliminary analysis of the TELLOMAK Phase II trial demonstrating clinical activity and a favorable safety profile for Lacutamab. The data were presented during the 2022 ASH (American Society of Hematology) Annual Meeting, in New Orleans (United States). Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Lacutamab description, mechanism of action, dosage and administration, research and development activities in Cutaneous T-cell lymphoma.
• Elaborated details on Lacutamab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Lacutamab research and development activity in Cutaneous T-cell lymphoma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Lacutamab.
• The report contains forecasted sales of Lacutamab for Cutaneous T-cell lymphoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cutaneous T-cell lymphoma.
• The report also features the SWOT analysis with analyst views for Lacutamab in Cutaneous T-cell lymphoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lacutamab Analytical Perspective by DelveInsight

• In-depth Lacutamab Market Assessment

This report provides a detailed market assessment of Lacutamab in Cutaneous T-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Lacutamab Clinical Assessment

The report provides the clinical trials information of Lacutamab in Cutaneous T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Cutaneous T-cell lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lacutamab dominance.
• Other emerging products for Cutaneous T-cell lymphoma are expected to give tough market competition to Lacutamab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lacutamab in Cutaneous T-cell lymphoma.
• Our in-depth analysis of the forecasted sales data from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lacutamab in Cutaneous T-cell lymphoma.

Key Questions

• What is the product type, route of administration and mechanism of action of Lacutamab?
• What is the clinical trial status of the study related to Lacutamab in Cutaneous T-cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lacutamab development?
• What are the key designations that have been granted to Lacutamab for Cutaneous T-cell lymphoma?
• What is the forecasted market scenario of Lacutamab for Cutaneous T-cell lymphoma?
• What are the forecasted sales of Lacutamab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Cutaneous T-cell lymphoma and how are they giving competition to Lacutamab for Cutaneous T-cell lymphoma?
• Which are the late-stage emerging therapies under development for the treatment of Cutaneous T-cell lymphoma?